

Journal of Visualized Experiments

Single-cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59809R2
Full Title:	Single-cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations
Keywords:	immunology; b cell; antibody; single cell cloning; immune repertoire; cell sorting; Flow cytometry; Alzheimer's; tau; antibody discovery; memory b cell
Corresponding Author:	Wouter Koudstaal Janssen Prevention Center Leiden, Zuid Holland NETHERLANDS
Corresponding Author's Institution:	Janssen Prevention Center
Corresponding Author E-Mail:	wkoudstaal@hotmail.com
Order of Authors:	Stuart T Perry Elissa Keogh Mike Morton Wouter Koudstaal Gabriel Pascual
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	San Diego, California United States

TITLE:

Single-Cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations

AUTHORS & AFFILIATIONS:

Stuart T. Perry¹, Elissa Keogh¹, Mike Morton¹, Wouter Koudstaal², Gabriel Pascual¹

¹World Without Disease Accelerator, Janssen Pharmaceutical Companies of Johnson and Johnson, San Diego, CA, USA

²Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands

Corresponding author:

Gabriel Pascual

gpascual@its.jnj.com

KEYWORDS:

B cell repertoire, B cell receptor, single cell cloning, cell sorting, antibody discovery, B cell cloning, memory B cell, heavy chain, light chain

SHORT ABSTRACT:

The BSelex method to identify and recover individual antigen-specific antibodies from human peripheral blood mononuclear cells combines flow cytometry with single cell PCR and cloning.

LONG ABSTRACT:

The human antibody repertoire represents a largely untapped source of potential therapeutic antibodies and useful biomarkers. While current computational methods, such as next generation sequencing (NGS), yield enormous sets of data on the antibody repertoire at the sequence level, functional data is required to identify which sequences are relevant for a particular antigen or set of antigens. Here, we describe a method to identify and recover individual antigen-specific antibodies from peripheral blood mononuclear cells (PBMCs) from a human blood donor. This method utilizes an initial enrichment of mature B cells and requires a combination of phenotypic cell markers and fluorescently-labeled protein to isolate IgG memory B cells via flow cytometry. The heavy and light chain variable regions are then cloned and re-screened. Although limited to the memory B cell compartment, this method takes advantage of flow cytometry to interrogate millions of B cells and returns paired heavy and light chain sequences from a single cell in a format ready for expression and confirmation of specificity. Antibodies recovered with this method can be considered for therapeutic potential, but can also link specificity and function with bioinformatic approaches to assess the B cell repertoire within individuals.

INTRODUCTION:

Antibodies are a growing class of therapeutic molecules, and the existing B cell repertoire in any human is a potential source of such antibodies. When recovered from a human donor, they

require no adaptation or “humanization”, steps that are required for antibodies generated in other animal systems. Several methods exist for the identification and isolation of human antibodies, including B cell activation and proliferation¹, immortalization via EBV transformation^{2,3}, and generation of hybridoma cell lines^{4,5}. However, all of these methods require extensive cell culture to screen and recover antigen-specific antibodies. Information about the human antibody repertoire has been greatly expanded with the development of next generation sequencing (NGS) technology, allowing for the identification of massive amounts of individual sequences present in donor samples. However, because NGS yields an agnostic view of all sequences present, it does not allow for the identification and isolation of antigen-specific antibodies, especially in the case of rare or low frequency antibodies.

The purpose of the “BSelex” method is to identify antigen-specific antibodies from circulating peripheral blood mononuclear cells in human donors, and isolate and recover the sequences of these antibodies for further analysis. This method utilizes flow cytometry and cell sorting to take advantage of the B cell receptor (BCR) expressed on the surface of memory B cells. Millions of B cells can be screened for antigen-specificity via flow cytometry before the more low-throughput molecular biology methods are initiated. Paired heavy and light chain identification is not possible in most NGS methods, which analyze cell sequences in bulk. In the method we describe here, cells are isolated individually, and paired recovery of both heavy and light chain sequences is possible, which allows direct cloning and expression of the full IgG.

PROTOCOL:

The use of samples from human volunteers followed protocols approved by The Scripps Research Institute Institutional Review Board. Informed consent was obtained from the donors prior to the blood donation.

1. Reagent preparation

1.1 Peripheral blood mononuclear cells (PBMCs)

1.1.1 Recover peripheral blood mononuclear cells from normal human donors by Ficoll-Plaque Plus isolation. Cryopreserve at 50 million cells/mL in 90% fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO). Freeze the cells at -80 °C and transfer to liquid nitrogen for long term storage.

1.2 Labeling target antigen peptides for sorting

1.2.1 Generate or obtain peptides specific to the target protein (up to 70 residues long) with a terminal biotin.

1.2.2 Label 4 nmol of each individual biotinylated peptide with streptavidin covalently attached to PE (R-phycoerythrin) or APC (allophycocyanin) in separate tubes. Prepare using a molar ratio of 9:1 peptide to streptavidin (SA), with a final concentration of roughly 3.2 μM for SA-PE and 5.7

89 μ M SA-APC. Prepare Biotin tetramers as a negative control.

90
91 1.2.3 Incubate each peptide mix overnight, in the dark, at 4 °C with slow mixing.

92
93 1.2.4 Remove unbound fluorophore by passing labeled peptides through microcolumns
94 containing polyacrylamide beads.

95
96 1.2.5 Store peptide tetramers up to 2 months at 4 °C.

97 98 **2. Cell sorting**

99
100 2.1 At least 1 hour up to 16 h before the CD22+ isolation, thaw donor PBMCs and allow to
101 rest at 37 °C.

102
103 2.1.1 Remove vials of frozen PBMCs from the freezer and immediately transfer to a 37 °C water
104 bath. When the vials are almost thawed, transfer to the work area.

105
106 2.1.2 Transfer the contents of each vial to a 50 mL tube containing prewarmed medium (keeping
107 the donors separate). Add medium to a final volume of 50 mL. Gently mix the contents.

108
109 2.1.3 Centrifuge at 370 x *g* for 6 min at room temperature. Discard the supernatant, resuspend
110 the cells in 15 mL of RPMI complete medium and perform a cell count.

111
112 2.1.4 Adjust cell concentration to 2.0×10^7 cells/mL with RPMI complete medium, and transfer
113 cells to a T75 flask or larger and incubate at 37 °C for at least 1 h and up to 16 h to allow recovery
114 time for thawed cells.

115
116 2.1.5 Collect the cells (pooling if desired) and centrifuge at 370 x *g* for 6 min at 4 °C. Discard
117 supernatant and resuspend the cells in 5 mL of ice cold MACS buffer (PBS, pH 7.6 containing 0.5%
118 BSA and 2 mM EDTA), bring to 50 mL with MACS buffer and perform a cell count.

119
120 2.1.6 Centrifuge the cells at 400 x *g* for 7 min at 4 °C.

121
122 2.1.7 Isolate the CD22+ B cells by positive selection via capture on CD22 microbeads. Use MACS
123 buffer for all washes. Count and centrifuge 400 x *g* for 7 min at 4 °C. The expected recovery is 5-
124 10% of the total PBMC population.

125
126 2.1.8 Resuspend cells at 40 million per mL FACS buffer (Tris buffer, pH 8.0 containing 0.5% BSA
127 and 2 mM EDTA) and proceed with cell staining of the donors individually or as a pool.

128
129 2.2 Stain cells for memory B cell sorting

130
131 2.2.1 Remove an aliquot of cells for cytometer set up and compensation for each of the labeling
132 fluorophores used. Include unstained cells as a control.

2.2.2 Calculate the final staining volume for the number of CD22⁺ cells obtained (staining 2 million per 100 μ L).

2.2.3 Add extracellular markers for B cells (CD19-PerCP-Cy5.5), IgG (IgG-FITC), and memory compartment (CD27-PECy7) as per manufacturers' dilution recommendations, and mix gently. Aliquot 10^7 cells into a 1.5 mL tube for the negative control and transfer the remaining cells to a 15 mL tube.

2.2.4 Add the dual labeled biotin-SA tetramers to the negative control tube at a final concentration of 36 nM each for PE and APC multiplied by the number of peptides in the sort tube and bring the volume to 0.5 mL final with FACS buffer (e.g., 10 peptides x 36 nM=360 nM).

2.2.5 Add the peptide tetramers to the sort tube at 36 nM each for PE and APC and bring the cells to 2×10^6 per 100 μ L with TBS Buffer. Incubate at 4 °C in the dark and with gentle rotation for 30-60 min.

2.2.6 Wash 2x at 4 °C, 400 x *g*, 7 min, removing an aliquot to count before the last wash. Filter cells using 5 mL filter cap tubes. Add DAPI (4',6-diamidino-2-phenylindole) stain to 0.3 μ M final concentration just prior to sorting as a marker of cell membrane integrity.

2.3 Single cell sorting via flow cytometry

2.3.1 Prepare 48 wells of 96-well PCR plates for sorting.

2.3.1.1 Prepare a master mix: (2 μ L of 10x RT buffer, 0.5 μ L of RNase inhibitor, 7.5 μ L of sterile PCR-grade water) per sample. Aliquot 10 μ L per well, cover, and store at 4 °C until ready for sort.

2.3.2 Run the negative control on the cell sorter, analyzing the entire sample.

2.3.2.1 Set flow cytometry gates to isolate the appropriate cell populations for single cell sorting.

2.3.2.1.1 Plot FSC area vs SSC area and set Gate R1 to isolate lymphocytes.

2.3.2.1.2 Plot FSC height vs FSC width and set Gate R3 to exclude FSC doublets.

2.3.2.1.3 Plot SSC height vs SSC width and set Gate R4 to exclude SSC doublets.

2.3.2.1.4 Plot SSC height vs DAPI and set Gate R5 to isolate live cells (DAPI⁻).

2.3.2.1.5 Plot IgG vs CD19 and set Gate R6 to isolate IgG⁺ B cells (CD19⁺ IgG⁺).

2.3.2.1.6 Plot IgG vs CD27 and set Gate R7 to select memory B cells (CD27^{high}).

2.3.2.1.7 Plot Antigen-PE (Ag-PE) vs antigen-APC (Ag-APC) and set Gate R8 as an Ag-PE⁺/Ag-APC⁺ quadrant with a low number of events in the double positive gate.

2.3.3 Collect an equal number of memory cells from the antigen-positive (Ag⁺) sample for determination of signal to noise.

2.3.4 Sort single cells having the phenotype CD19⁺ CD27⁺ Ag-PE⁺ Ag-APC⁺ (Gate R8) into prepared 96-well PCR plates.

2.3.5 Cover plates with aluminum tape pads, centrifuge for 1 min at 400 x g, and store at -80 °C for future cloning.

3. Single cell cloning

3.1 Reverse transcription reactions

3.1.1 Remove the single B cell sort plate from 80 °C. Thaw on ice for 2 min. Spin the plate for 2 min at 3,300 x g to pool contents in the bottom of the wells before opening.

3.1.2 Prepare a dNTP/buffer master mix with 10% non-ionic detergent and oligo(dT) as the reverse primer. Add enzyme mix to each well containing the single cell and **DO NOT MIX**.

3.1.3 Incubate 5 min at 65 °C. Add enzyme master mix containing 100 mM DTT, RNase inhibitor, and reverse transcriptase enzyme to bring total volume to 20 µL. Incubate 10 min at 50 °C, then 10 min at 80 °C.

3.1.4 Transfer to ice prior to starting PCR steps

3.2 Multi-step nested PCR reactions

3.2.1 Use separate nested PCR reactions are used for heavy chain (HC) and light chain (LC) amplification.

3.2.2 For the first round of PCR amplification (Step I), use a pool of forward primers and a single reverse primer to amplify the HC and LC variable regions in separate PCR reactions (**Figure 2**). By design, the pool of forward primers will amplify a large percentage of germline leader (L) sequences and the reverse primer is specific to the downstream constant regions of each chain, including both the kappa (κ) and lambda (λ) for light chains¹⁶.

3.2.2.1 Use 2.5 µL of cDNA product as template for each PCR (Step I) reaction. Add primers to the final reaction concentration of 1 µM for each. Double the 10x polymerase buffer to 2x concentration, bring the final volume to 25 µL per reaction. Run HC PCR reactions using [94 °C/4 min; 94 °C /15 s, 55 °C /20 s, 68 °C/60 s; 68 °C/3 min] for 50 cycles. Run LC PCR reactions using [98 °C/4 min; 98 °C /15 s, 72 °C /20 s, 72 °C/60 s; 72 °C/3 min] for 50 cycles.

3.2.3 Use 2.5 μ L of the Step I product as template for each (Step II) PCR reaction. Add the pool of forward primers specific to the HC and LC (κ and λ) framework 1 region and a pool of reverse primers specific to the junction region of each antibody chain. Double the 10X polymerase buffer to 2X concentration, and run PCR reactions 50 cycles each using the same parameters as Step I.

3.2.4 Run the completed PCR reactions on 1% agarose gel to visualize positive amplification hits. Recover paired amplicons (both heavy and light chain from the same cell) and isolate via gel extraction. Determine DNA fragment concentration via OD₂₆₀ for accurate ligation mix calculations.

3.2.5 Combine recovered heavy and light chain fragments with a linker fragment and the expression vector backbone using a 4-fragment ligation reaction using a commercial kit.

3.2.6 Transform ligation reactions into chemically competent bacteria using a commercial kit. Once plated onto antibiotic plates, add 4 mL of growth media (with antibiotic) to the remaining transformation culture, and incubate 37 °C overnight at 250 rpm. This is the “ligation mix culture.”

3.2.7 Prepare miniprep DNA from the overnight ligation mix cultures using a commercial kit, and determine the resulting plasmid DNA concentration.

4. ELISA screen for confirmation of antigen-specificity

4.1 Transfect 10 μ g of miniprep DNA with cationic lipid-based reagent into 10 mL of suspension 293 cells, and incubate for 3-4 days at 37 °C (8% CO₂) while rotating at 125 rpm. For harvest, centrifuge culture 10 min at 1,000 x *g* and recover clarified media.

4.1.1 Measure the IgG concentration in the supernatants via affinity to Protein A.

4.1.2 Test each IgG (in supernatant) at 20 μ g/mL by enzyme-linked adsorbent assay (ELISA) against the individual peptides used for the sort, captured on a streptavidin plate or actin as a negative control. Use a goat anti-human peroxidase secondary antibody against human IgG Fab to detect recombinant clones. After subtraction of background, OD > 0.5 is defined as screen positive.

4.1.3 Confirm screen positive hits by performing an additional ELISA, using dilutions of IgG supernatant to generate a concentration curve starting at 20 μ g per mL, and plotting against OD for each antigen showing reactivity in the initial screen ELISA.

REPRESENTATIVE RESULTS:

This method covers a multi-step process to isolate antigen-specific antibodies from human donors. In the representative data shown here, cells were incubated with a pool of fluorescently-labeled peptides representing several different domains of the tau protein, including

phosphorylated peptides to mimic putative phosphorylation sites. These peptides were used as “bait” to identify cells that are reactive with tau epitopes(s) of interest. In preparation for sorting, a panel of fluorescently-labeled phenotypic markers were used to identify different cell populations within the enriched B cell population. A series of cytometry gates were devised to isolate the target memory B cells (**Figure 1**). Lymphocytes were isolated based on their cell size and granularity using forward scatter (FSC) and side scatter (SSC) plots in flow cytometry^{6,7}. Following exclusion of multiple cells (“doublets”) and dead cells, phenotypic markers allowed the segregation of IgG⁺ memory B cells via IgG, CD19 (B cell) and CD27 (memory). In this approach, the CD27 marker does not distribute into two discrete populations, so the top 45% of CD27⁺ expressing cells are included for the final gate. Finally, cells double-positive for both APC and PE fluorophores distribute into the upper right quadrant of the gating graph, indicating reactivity to both labeled versions of peptides. The cells that fell within the drawn gate were isolated and sorted into individual wells of a 96-well plate. The use of antigen with two different labels increases the signal-to-noise ratio and reduces the number of false positives in the subsequent molecular biology process. The sorted cells represented about 0.1% of the memory B cells in the final gate, and 0.001% of the starting cell sample.

The first readout of single cell cloning is confirmation of amplification of the respective heavy and light variable chains (**Figure 2**). Since paired recovery of both amplicons is desired, the PCR reactions are evaluated side-by-side on agarose gel, and matched pairs are excised from the gel and DNA fragments extracted. Typical efficiency of amplification is 30-50% heavy chain and 50-70% light (kappa) chain. Recovery of paired amplicons is usually between 25-40% efficiency. These efficiencies vary between donor pools, and the representative data (**Figure 3**) is an example of very efficient amplification from 24 single cells (42% paired recovery). Following IgG cloning, the IgG expression vector is transfected into human embryonic kidney (HEK-293) suspension cells, which are used to maximize expression. The use of serum-free medium reduces contaminating proteins from the recombinant antibody prep, and helps minimize noise in subsequent binding assays. The recovered antibodies are screened against the original panel of tau peptides and scored for reactivity by ELISA (**Figure 4**). An initial threshold of OD = 0.5 above background is used to indicate positive antigen reactivity, and β -actin protein is used as a control for non-specific binding. If the flow cytometry and sorting steps use a mixed pool of peptides, the screening ELISA is the first step of deconvoluting specific reactivities of the recovered IgGs. Three of the 10 IgGs assayed demonstrated reactivity against phosphorylated CBTAU22.1 peptide, and one was reactive to non-phosphorylated CBTAU27.1 (**Figure 4A**). Additional confirmation was completed using a concentration curve of the same recombinant antibody samples against the peptides identified in the initial screen, and an additional peptide as a negative control (**Figure 4B**). For each positive hit, an individual plasmid clone was isolated from the transformed pool and reconfirmed by the same ELISA method. Only Clone 34 is shown the data presented, and while reactivity to non-phosphorylated CBTAU27.1 was confirmed, lower affinity binding was also observed with the phosphorylated 27.1 peptide (**Figure 4C**).

FIGURE AND TABLE LEGENDS:

Figure 1: Isolation of antigen-reactive single cells via flow cytometry. A) Shown is a representative plot where the lymphocyte population was contained within the drawn gate. B)

Gates based upon forward and side scatter (FSC-height v FSC-width (R3); SSC- height v SSC-width(R4)) were used to exclude doublets. Only cells within drawn gates were evaluated in subsequent plots. DAPI⁺ cells were considered dead and excluded (R5). In this experiment, 3.7x10⁷ “live” cells were interrogated. The majority of live cells were B cells (CD19⁺), and IgG⁺ cells (4.66%) were isolated from this population (R6). The top 43.2% of CD27⁺-expressing memory cells were included in the selection gate (R7). C) Quadrant 2 (Q2) contained cells reactive to both labeled antigens (peptide-APC v peptide-PE), and these cells were sorted and recovered individually into a 96-well plate.

Figure 2: PCR amplification recovers IgG heavy and light variable sequence for cloning. A) Both heavy (VH) and light (Vk or Vλ) chain variable regions are recovered using nested PCR reactions. Step I primers amplify forward from the native leader sequence and reverse from within the constant region. Multiple arrows represent a pool of between 7-12 primers, which are used to ensure broad coverage of possible germlines. Step II primers are nested, specific to the extreme ends of the variable open reading frame, and add sequence to the ends of the amplicons that are homologous to adjacent sequence in the expression vector. B) The linker consists of the constant light chain (Cκ or Cλ), followed by the heavy chain promoter and a non-native signal peptide sequence. The amplicons, linker, and plasmid backbone are simultaneously ligated via overlapping homologous sequence generated during the Step II PCR amplification, and isolated as an intact plasmid. The recombinant heavy and light chains in the final expression vector are driven by independent (and identical) CMV promoters, and are translated as separate proteins.

Figure 3: IgG heavy and light variable chain amplicons are recovered from single cells. The nested PCR reactions (Step II) were directly loaded onto 1% agarose gel and visualized. Heavy chain (H) and kappa light chain (L) PCR reactions from the same cell were loaded in adjacent wells so paired amplicons were easily observed. Successful heavy and light chain products are roughly 400 bp and 350 bp respectively. Successful recovery of paired amplicons are denoted by an (*).

Figure 4: Antigen specificity is confirmed from recombinant IgGs. Plasmids containing the recovered heavy and light chain sequences are transfected into HEK cells for expression. After four days, recombinant antibodies are assessed for reactivity by ELISA. (A) IgG concentration in the clarified media was measured and diluted to 20 µg/mL. The pool of peptides used for sorting were individually assessed using 40 pmol per well in streptavidin plates. All IgGs were tested in duplicate wells. (B) Clones that displayed OD450 measurement >0.5 were re-assessed (Clones #32, #34, #35) using 1:5 dilution steps against the peptides identified in the screen. (C) Once confirmed as a hit, a single plasmid clone was isolated from the clone #34 transformed ligations, transfected, and reconfirmed by ELISA. The same was done for clones #32 and #35 (data not shown).

DISCUSSION:

The method presented here combines flow cytometry and single cell cloning, and the methods we describe here we based on methods previously developed by Tiller and colleagues¹¹. Their work describes the recovery and cloning of monoclonal antibodies in order to study the B cell repertoire in humans at the level of individual cells. We have adapted the major components of

their process to allow recovery of antigen-specific monoclonal antibodies from a population of memory B cells, including the multi-step amplification primer strategy. The major modification is the addition of labelled antigen “bait”. Additional adaptations have been made to the published protocol, including (but not limited to) modifying the cloning vector backbone into a single expression plasmid, additional primer coverage of the germline repertoire (both leader sequence and framework 1), transfection of suspension HEK293 cells for higher expression, and the use of high fidelity polymerases during PCR amplification.

For the methods described here, the most critical steps are near the transition between flow cytometry and single cell cloning. First, the proper placement of sorted single cells into the plate is essential. Setting the drop-delay correctly on the sorter is a key step. Environmental factors, such as low humidity, must also be taken into account, as we have found our recovery efficiencies drop significantly unless a static gun is used on the target sort plates. Following cell placement, plates are centrifuged to ensure cells have contacted the 10 μ L of buffer in bottom of the wells. All of these measures are critical for the molecular biology portion to be successful. If the conditions are sub-optimal for the reverse transcription reaction of a single cell, PCR amplification of even β -actin can be difficult. The strength of the method presented is the ability to interrogate millions of cells and only sort the ones that match the antigen reactivity criteria against the antigen of choice. This requires the signal to noise ratio to be as high as possible, which is done by optimizing bait concentrations before sorting. Dual-labeled bait is used to reduce the recovery of false-positive cells, which can occur if one of the fluorophores has high background. Using more than one antigen bait can make the signal:noise optimization more difficult, but the ability to interrogate multiple peptides simultaneously is another benefit of this method.

When recovery efficiencies are low, a set of nested β -actin primers are used to confirm that template cDNA is present. The drawback to this approach is that it is difficult to determine whether there was no cell present in the well or the reverse transcription reaction failed, making troubleshooting difficult. Occasionally the opposite will occur and the efficiencies are higher than expected. The typical recovery for heavy chain is between 30-45% and light chains are higher, between 40-60%. Each PCR reaction (Step I & II) uses 50 cycles to amplify from a single cell. The high number of total cycles also makes this method susceptible to contamination. Sequence analysis of amplicons can be used to determine whether a contaminant has been introduced, or an unusually high recovery rate has been legitimately achieved.

The utility of this method to recover native human antibodies against an antigen of choice has several significant limitations. First, only soluble proteins that can be labeled may be used as “bait” for the flow cytometry. For the sorts presented in the representative results, we used a series of synthesized overlapping peptides from tau protein, since using the whole protein proved difficult. The use of linear peptides is likely not optimal, since it may limit the identification of antibodies against non-linear or structural epitopes. However, we were able to identify several unique antibodies against tau and these are currently undergoing further evaluation^{8,9}. Another limitation is the low throughput of the molecular biology recovery and cloning of IgGs. The initial sorting strategy allows for the screening of millions of cells, but the subsequent molecular biology processing consists of multiple stages. Ongoing optimization efforts to incorporate newer

technologies, such as Gibson Assembly¹⁰ have streamlined several steps, but the bottleneck remains cloning individual heavy and light chain pairs.

The “BSelex” method utilizes the BCR expressed on the surface of memory B cells to identify cells that display antigen reactivity, and then recover these individual cells via flow cytometry^{11,12}. Due to this reliance on the BCR, the method is restricted to the memory B cell compartment, and does not capture antibody secreting cells (ASCs) such as plasmablasts. However, this approach may be advantageous to recovering a broader repertoire of antigen-specific immunoglobins when compared to ASCs. Influenza vaccination studies demonstrate that while reactive ASCs can be dominated by a small number of expanded B cell clones, the antigen-specific memory B cell population is rarely clonal¹². The T cell receptor (TCR) on the surface of T cells possesses similarities to the B cell receptor in gene arrangement and recombination to maximize diversity. Single cell approaches similar to what is described in the method presented here have been developed for assessing the T cell repertoire, including recovery and single cell cloning of alpha and beta chains¹³. However, TCR recognition requires peptides to be presented by MHC molecules, adding significant complexity to the labeled bait approach to identify peptide-specific T cells. Unlike B cells, T cells do not undergo affinity maturation of the entire variable region, so identification of the short CDR3 region and some flanking sequence is all that is required for identification and reconstitution. Finally, this method describes the identification of IgG molecules using flow cytometry, but it is also possible to use alternative phenotypic markers to identify B cells of different isotypes.

Currently, there are methods being developed to connect the enormous amount of data collected from next generation sequencing with functional analysis of antigen specificity, but these methods are still being refined. Despite its limitations, the method described here has been used to identify antibodies with potential therapeutic value for both infectious and non-infectious diseases^{8,14,15}, and represents a reliable approach to recover relevant antigen-specific IgGs from humans, without extensive manipulation of B cells or extensive cell culture.

ACKNOWLEDGMENTS:

The authors would like to thank Lucy Chammas, Martha Costa, Julie Kim, Nancy Heredia, and Jeremy Macedo for the extensive testing of many method modifications and refinement of the current BSelex platform.

DISCLOSURES:

The authors have nothing to disclose

REFERENCES:

- 1 Su, K. Y., Watanabe, A., Yeh, C. H., Kelsoe, G., Kuraoka, M. Efficient Culture of Human Naive and Memory B Cells for Use as APCs. *Journal of Immunology*. **197** (10), 4163-4176 (2016).
- 2 Corti, D., Lanzavecchia, A. Broadly neutralizing antiviral antibodies. *Annual Review of Immunology*. **31** 705-742 (2013).
- 3 Steinitz, M., Klein, G., Koskimies, S., Makel, O. EB virus-induced B lymphocyte cell lines producing specific antibody. *Nature*. **269** (5627), 420-422 (1977).

- 441 4 Bloom, A. D., Nakamura, F. T. Establishment of a tetraploid, immunoglobulin-producing
442 cell line from the hybridization of two human lymphocyte lines. *Proceedings of the National*
443 *Academy of Sciences of the United States of America*. **71** (7), 2689-2692 (1974).
- 444 5 Olsson, L., Kaplan, H. S. Human-human hybridomas producing monoclonal antibodies of
445 predefined antigenic specificity. *Proceedings of the National Academy of Sciences of the United*
446 *States of America*. **77** (9), 5429-5431 (1980).
- 447 6 Lechner, J. et al. Alterations in Circulating Immune Cells in Neovascular Age-Related
448 Macular Degeneration. *Scientific Reports*. **5** 16754 (2015).
- 449 7 Loken, M. R., Brosnan, J. M., Bach, B. A., Ault, K. A. Establishing optimal lymphocyte gates
450 for immunophenotyping by flow cytometry. *Cytometry*. **11** (4), 453-459 (1990).
- 451 8 Pascual, G. et al. Immunological memory to hyperphosphorylated tau in asymptomatic
452 individuals. *Acta Neuropathologica*. **133** (5), 767-783 (2017).
- 453 9 van Ameijde, J. et al. Enhancement of therapeutic potential of a naturally occurring
454 human antibody targeting a phosphorylated Ser(422) containing epitope on pathological tau.
455 *Acta Neuropathologica Communications*. **6** (1), 59 (2018).
- 456 10 Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases.
457 *Nature Methods*. **6** (5), 343-345 (2009).
- 458 11 Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by
459 single cell RT-PCR and expression vector cloning. *Journal of Immunological Methods*. **329** (1-2),
460 112-124 (2008).
- 461 12 Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against
462 influenza virus. *Nature*. **453** (7195), 667-671 (2008).
- 463 13 Han, A., Glanville, J., Hansmann, L., Davis, M. M. Linking T-cell receptor sequence to
464 functional phenotype at the single-cell level. *Nature Biotechnology*. **32** (7), 684-692 (2014).
- 465 14 Apetri, A. et al. A common antigenic motif recognized by naturally occurring human VH5-
466 51/VL4-1 anti-tau antibodies with distinct functionalities. *Acta Neuropathologica*
467 *Communications*. **6** (1), 43 (2018).
- 468 15 Jones, H. G. et al. Structural basis for recognition of the central conserved region of RSV
469 G by neutralizing human antibodies. *PLoS Pathogens*. **14** (3), e1006935 (2018).
- 470 16 U.S. Patent Application No. 20170210787, Published July 27, 2017; (Janssen Vaccines &
471 Prevention B.V., Applicant)
- 472

Figure 1










Figure 2**A)***Light chain**Heavy chain*

Step I
PCR
Step II

B)*Linker**Ligation*

Expression vector

Figure 3





Figure 4



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
MoFlo Astrio EQ, Cell Sorter	MoFlo		cell sorting
Biotinylated peptides	New England Peptide		Cell sorting "bait"
Micro Bio-spin P30 gel column	BioRad	#7326223	
Streptavidin (R-PE)	Thermo Scientific	SA10041	
Streptavidin (APC)	Thermo Scientific	S32362	
CD22 MicroBeads, human	Miltenyi	#130-046-401	
LS columns	Miltenyi	#130-042-401	
Pre separation filters	Miltenyi	#130-041-407	
PerCp-Cy5.5 mouse anti-human CD19	BD Biosciences	BD#340951	
PE-Cy7 mouse anti-human CD27	BD Biosciences	#560609	
FITC mouse anti-human IgG	BD Biosciences	#560952	
DAPI	Life Technologies	#D21490	
RNaseOUT	Life Technologies	#10777-019	
Bovine serum albumin, Fraction V	Sigma	#A4503	
RPMI media	Hyclone	#SH30096.01	
HI FBS (Fetal bovine serum)	Invitrogen	#10082147	
Mastercycler Gradient	Eppendorf	Model #6325	PCR machine
PCR 96-well plates	Phenix	MPS-500	
PCR Plate mats	Phenix	SMX-PCR96	
Advantage UltraPure PCR			Primers for all PCR steps
Deoxynucleotide Mix	Clontech	#639125	
Superscript IV First-strand synthesis system	Invitrogen	#18091050	
Phusion High Fidelity Polymerase	Thermo Scientific	F-531-L	
Platinum polymerase	Invitrogen	#10966108	
Nuclease-free water	QIAGEN	#129114	
Oligonucleotide primers	IDT	assorted	
Gel Extraction Kit	QIAGEN	#28706	

PCR Purification kit	QIAGEN	#28106	
Miniprep Kit	QIAGEN	#27106	
NEBuilder HiFi DNA Assembly Cloning Kit	New England Biolabs	E5520S	Gibson assembly
Expi293 Expression Media	Invitrogen	#A14351-01	
ExpiFectamine 293 Transfection Kit	Invitrogen	#A14525	
Opti-MEM Media	Invitrogen	#31985070	
CO2 incubator (Multitron)			
Octet RED384 System	Pall/ Forte Bio		
Pierce Streptavidin Coated High Binding Capacity Clear 96-well Plates	Thermo Scientific	#15500	
Corning Costar 96-well Polystyrene Plate High Binding Half Area	Corning	#3690	
Goat Anti-human IgG Fab Secondary Antibody	Jackson Labs	#109-036-097	
Goat Anti-mouse HRP Secondary Antibody	Jackson Labs	#115-035-072	
SureBlue™ TMB Microwell Peroxidase Substrate (1-Component)	KPL	#52-00-03	
TMB Stop Solution	KPL	#50-85-06	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Single cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations
Author(s):	Stuart Perry, Elissa Keogh, Mike Morton, Wouter Koudstaal, Gabriel Pascual

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access

☒ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Gabriel Pascual	
Department:	Janssen Prevention Center	
Institution:	Janssen Pharmaceutical Companies of Johnson & Johnson	
Title:	Single cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations	
Signature:		Date: 3/5/2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



World Without Disease Accelerator
Janssen R&D
3210 Merryfield Row
San Diego, CA

March 27, 2019

Dear Dr. Myers,

Please find a revised version our manuscript entitled **‘Single-cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations’** by Stuart T. Perry *et al.* that that we hope is now acceptable for publication.

We include a point-by-point response to the specific comments raised by the reviewers. In addition, we have made the required changes to the editorial comments that were noted. Please do not hesitate to reach out if you have any further questions.

Sincerely Yours,

Gabriel Pascual, Ph.D.

WWDA, Janssen Pharmaceutical Companies of Johnson & Johnson

858-320-3444 (Office); 858-336-8471 (Cell)
gpascual@its.jnj.com

Editorial comments:

Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

We were unable to obtain the necessary documents to reproduce this figure (Figure 1) from our prior publication, so we omitted it. One of the reviewers thought this figure was unnecessary, so we replaced it with a requested figure outlining the PCR strategy and expression vector.

Please specify primers for PCR reactions.

The primer sequences used for this work are currently listed in a related patent application, and will not be included in this manuscript. (Reference: US Patent Application for ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THAT SPECIFICALLY BIND TO MICROTUBULE-ASSOCIATED PROTEIN TAU Patent Application (Application #20170210787). We have added this to the references.

Please do not abbreviate journal titles for references.

We are unclear on what to change. The Instructions for Authors sheet uses the an example with abbreviated Journal titles, and in reference to citations: "Write journal names in italics and list using standard abbreviations with periods." If we have misunderstood, or the convention has changed, we can change the references accordingly.

Reviewers' comments:

Reviewer #1:

2.1.4: Justify the step of incubation at 37°C

This incubation is done to give the cells a chance to recover from thawing. This has been added to the manuscript text.

2.1.7: Justify the enrichment of CD22+ B cells

CD22 antigen is a marker for mature B cells, and is lost during terminal differentiation into plasma cells. CD22+ enrichment is performed to reduce the total number of cells in the labelled sample to be sorted.

The step 2.1.4 is unnecessary as already described in step 2.3.1

We have found the duplication between Step 2.3.1 and 2.4 and removed it from the text.

3.1.3: Precise the final volume of RT reaction

This has been added to the protocol text.

3.2: Precise the final volumes of PCR reactions

This has been added to the protocol text.

4.1: Give some details of the transfection method and justify the choice of serum-free medium

The only additional detail is the volume of suspension cells, which has been added to the protocol text. The reagents used are on the materials sheet. There is nothing added beyond the manufacturer's recommended protocol. Text has been added to the Representative Results section to justify the use of serum-free medium.

Figure 2: The dot plot in C shows Tau-peptide-APC versus SSC instead Tau-peptide-APC versus Tau-peptide-PE.

This has been corrected on Figure 2

Line 248: Three (not two) of the 10 IgGs demonstrated reactivity...

This has been corrected in the text.

Reviewer #2:

Minor Concerns:

Can the authors comment on the reason why they optimize their protocol for isolating say naive B cells or plasmablasts and chose memory B cells? I think this should be addressed in the introduction

We specifically use the memory B cells because they possess the BCR on the plasma membrane, and opposed to antibody-secreting cells, which produce soluble antibody that no longer associates with the cell once released. The surface expression allows the coupling of cell type identification with antigen specificity via flow cytometry. Although we do not mention plasmablasts or naïve cells in the introduction, we describe the advantage of using memory cells in the discussion. Additional text has been added to clarify this rationale.

In line 91, can the peptides be tested/validated before storing, If so, how?

We typically generate tetramers prior to a sort experiment, then store the remaining peptide for the next sort. This means the "validation" occurs during the first sort, and we have repeatedly demonstrated consistent results from the stored reagent. We did not add this to the discussion because it seemed a minor point.

On the centrifugation steps in some cases the authors recommend 370g and in others 400g. May you provide an explanation on why this difference and would it affect the experiment to do all steps at 400g?

The different speed settings are an internal modification we added. The goal is to pellet the cells as gently as possible, and this modification accomplishes that. However, performing this step at 400xg throughout would likely have the same outcome.

Is there a reason why the authors do not recommend using compensation beads? and use cells instead?

Since the compensation beads bind extremely well, we believe cells are more representative and therefore more relevant to the experimental conditions. The cell populations used for compensation settings are in sufficient numbers to make the correct assessment.

On line 123 point 2.2.3 May the authors provide a recommended dilution for the antibodies

We use the dilution recommended by the manufacturer for each of the markers. This has been added to the text.

On line 134 point 2.2.6 the authors recommend the use of DAPI, is it possible to replace DAPI for any other fluorescent live/dead marker?

We have successfully used alternative live-dead reagents to DAPI. This allows alternative channels or fluorophores to be used if necessary.

Figure 1 seems unnecessary, I would rather see a figure of the cloning strategy (plasmid map, enzymes used, linker position, etc..).

We removed Figure 1 and added a figure that outlines the PCR and cloning strategy. This includes an outline of the final expression plasmid, and the arrangement of heavy and light chain expression cassettes.

It is not clear in the text where the Opti-MEM media should be used.

Optimem is used in the transfection protocol to dilute DNA and lipid, and is detailed in the manufacturer's instructions for the transfection reagent.

Reviewer #3:

Major Concerns:

The authors describe the production of peptides with a biotin label as antigen. As a result, the B-cells captured will most likely recognise linear epitopes, as these peptides will not have the native structure nor post-translational modifications. This should be explicitly stated. Perhaps it is wise to explain why this approach was taken and in which cases such an approach might suffice (as I can imagine that in many, it won't).

In the discussion section we specifically mention whole proteins used as bait, and the limitations of issues with proteins that are not soluble. For the representative results, we used linear peptides for the example since that is what we have most recently published. We added text that addresses linear peptides to the discussion.

The authors should provide details of the PCR primers, mixed and PCR conditions, including Taq enzyme

The primers and conditions can be found in the referenced patent application. The PCR conditions were added to the protocol steps. We only used high fidelity polymerases, and did not use Taq polymerase, so this was not listed in the protocol or the materials.

Similarly, the authors should provide details of the vector backbone.

A new figure has been added (Figure 2) which consists of an overview of the cloning strategy and expression vector, including the backbone. The final expression plasmid, and the arrangement of heavy and light chain expression cassettes are described.

The single cell PCR method seems to be a derivative from the protocol that was started in the Nussenzweig lab (Wardeman 2002). Perhaps good to refer to that and to explain if and why these modifications here were chosen.

This method is a derivative of a more current protocol from the Nussenzweig lab, and this paper is cited in the references (Tiller, et al.). Additionally, a new paragraph was inserted into the discussion that addresses this similarity, and briefly describes the differences between the two.

T-cells do not have a heavy and a light chain. They have a TCR α and a TCR β chain (or TCR γ and TCR δ). These are very similar in size, with all having 1 IgV and 1 IgC domain, thus cannot be called 'heavy' and 'light'. The major differences with B cells is that T-cells do not just recognise antigen. The antigen peptides needs to be presented by MHC molecules, and thus require MHC tetramers with additional challenges due to the variability in MHC between individuals

The reviewer is correct. We modified the text to reflect this distinction between BCR and TCR and in the discussion.

The efficiency to obtain both an IgH and an IgL from a single B cells seems quite low from Figure 3. Is this representative? And can the authors state the total efficiency? How does this relate to other publications with single cell Ig amplification? Is this a technical challenge with cDNA reaction and/or PCR, or is this due to low purity of sorted cells? The stains in Fig 2 are not super strong, and perhaps inclusion of CD3, as well as IgM and IgD can be used to exclude T-cells and naive and IgM memory B cells.

The reviewer raises a good point. This gel is fairly representative of the amplification efficiencies for both heavy and light chain, the number of paired fragments is NOT representative. We have replaced with another set of gels to more accurately represent our normal results. We have added additional text in the Representative Results section referring to this figure and the efficiency observed.

Minor Concerns:

Abstract: 'interrogate of millions of B cells': remove first 'of'

Introduction, first sentence: change into 'molecules'

Both issues have been corrected in the text.



World Without Disease Accelerator
Janssen R&D
3210 Merryfield Row
San Diego, CA

April 12, 2019

Dear Dr. Myers,

Please find a revised version our manuscript entitled **‘Single-cell screening method for the selection and recovery of antibodies with desired specificities from enriched human memory B cell populations’** by Stuart T. Perry *et al.* that that we hope is now acceptable for publication.

We include a point-by-point response to the specific comments raised by the reviewers. In addition, we have made the required changes to the editorial comments that were noted after both the first submission and subsequent revision. Please do not hesitate to reach out if you have any further questions.

Sincerely Yours,

Gabriel Pascual, Ph.D.

WWDA, Janssen Pharmaceutical Companies of Johnson & Johnson

858-320-3444 (Office); 858-336-8471 (Cell)
gpascual@its.jnj.com

Editorial comments (R1):

The following issues with manuscript 59809_R1.docx have been addressed:

2. Please use a single space between numerical values and their units.

These edits have been made to the manuscript.

3. Step 2.1.3: Discard the supernatant?

The instruction to “discard the supernatant” has been added to the manuscript.

4. 2.1.4: 20x10⁶ per mL?

This value has been changed to “2.0 x 10⁷” for clarity.

5. 2.1.5: Discard the supernatant?

The instruction to “discard the supernatant” has been added to the manuscript.

6. 2.1.7: What is used to wash the cells? TBS buffer?

The buffer is the MACS buffer described previously. This has been modified in the text for clarity.

7. 4.1.2: Please specify the antibodies.

The IgGs tested are the recombinant antibodies in the supernatant. The secondary antibody is in the materials section, and has been modified in the manuscript for clarity.

8. 4.1.3: Please write this step in the imperative tense.

This edit has been made to the manuscript.

Please do not abbreviate journal titles for references.

We edited reference journal titles to remove all abbreviations.

Editorial comments (R0):

Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. “This figure has been modified from [citation].”

We were unable to obtain the necessary documents to reproduce this figure (Figure 1) from our prior publication, so we omitted it. One of the reviewers thought this figure was unnecessary, so we replaced it with a requested figure outlining the PCR strategy and expression vector.

Please specify primers for PCR reactions.

The primer sequences used for this work are currently listed in a related patent application, and will not be included in this manuscript. (Reference: US Patent Application for ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THAT SPECIFICALLY BIND TO

MICROTUBULE-ASSOCIATED PROTEIN TAU Patent Application (Application #20170210787). We have added this to the references.

Reviewers' comments:

Reviewer #1:

2.1.4: Justify the step of incubation at 37°C

This incubation is done to give the cells a chance to recover from thawing. This has been added to the manuscript text.

2.1.7: Justify the enrichment of CD22+ B cells

CD22 antigen is a marker for mature B cells, and is lost during terminal differentiation into plasma cells. CD22+ enrichment is performed to reduce the total number of cells in the labelled sample to be sorted.

The step 2.1.4 is unnecessary as already described in step 2.3.1

We have found the duplication between Step 2.3.1 and 2.4 and removed it from the text.

3.1.3: Precise the final volume of RT reaction

This has been added to the protocol text.

3.2: Precise the final volumes of PCR reactions

This has been added to the protocol text.

4.1: Give some details of the transfection method and justify the choice of serum-free medium

The only additional detail is the volume of suspension cells, which has been added to the protocol text. The reagents used are on the materials sheet. There is nothing added beyond the manufacturer's recommended protocol. Text has been added to the Representative Results section to justify the use of serum-free medium.

Figure 2: The dot plot in C shows Tau-peptide-APC versus SSC instead Tau-peptide-APC versus Tau-peptide-PE.

This has been corrected on Figure 2

Line 248: Three (not two) of the 10 IgGs demonstrated reactivity...

This has been corrected in the text.

Reviewer #2:

Minor Concerns:

Can the authors comment on the reason why they optimize their protocol for isolating say naive B cells or plasmablasts and chose memory B cells? I think this should be addressed in the introduction

We specifically use the memory B cells because they possess the BCR on the plasma membrane, and opposed to antibody-secreting cells, which produce soluble antibody that no longer associates with the cell once released. The surface expression allows the coupling of cell type identification with antigen specificity via flow cytometry. Although we

do not mention plasmablasts or naïve cells in the introduction, we describe the advantage of using memory cells in the discussion. Additional text has been added to clarify this rationale.

In line 91, can the peptides be tested/validated before storing, If so, how?

We typically generate tetramers prior to a sort experiment, then store the remaining peptide for the next sort. This means the “validation” occurs during the first sort, and we have repeatedly demonstrated consistent results from the stored reagent. We did not add this to the discussion because it seemed a minor point.

On the centrifugation steps in some cases the authors recommend 370g and in others 400g. May you provide an explanation on why this difference and would it affect the experiment to do all steps at 400g?

The different speed settings are an internal modification we added. The goal is to pellet the cells as gently as possible, and this modification accomplishes that. However, performing this step at 400xg throughout would likely have the same outcome.

Is there a reason why the authors do not recommend using compensation beads? and use cells instead?

Since the compensation beads bind extremely well, we believe cells are more representative and therefore more relevant to the experimental conditions. The cell populations used for compensation settings are in sufficient numbers to make the correct assessment.

On line 123 point 2.2.3 May the authors provide a recommended dilution for the antibodies

We use the dilution recommended by the manufacturer for each of the markers. This has been added to the text.

On line 134 point 2.2.6 the authors recommend the use of DAPI, is it possible to replace DAPI for any other fluorescent live/dead marker?

We have successfully used alternative live-dead reagents to DAPI. This allows alternative channels or fluorophores to be used if necessary.

Figure 1 seems unnecessary, I would rather see a figure of the cloning strategy (plasmid map, enzymes used, linker position, etc..).

We removed Figure 1 and added a figure that outlines the PCR and cloning strategy. This includes an outline of the final expression plasmid, and the arrangement of heavy and light chain expression cassettes.

It is not clear in the text where the Opti-MEM media should be used.

Optimem is used in the transfection protocol to dilute DNA and lipid, and is detailed in the manufacturer’s instructions for the transfection reagent.

Reviewer #3:

Major Concerns:

The authors describe the production of peptides with a biotin label as antigen. As a result, the B-cells

captured will most likely recognise linear epitopes, as these peptides will not have the native structure nor post-translational modifications. This should be explicitly stated. Perhaps it is wise to explain why this approach was taken and in which cases such an approach might suffice (as I can imagine that in many, it won't).

In the discussion section we specifically mention whole proteins used as bait, and the limitations of issues with proteins that are not soluble. For the representative results, we used linear peptides for the example since that is what we have most recently published. We added text that addresses linear peptides to the discussion.

The authors should provide details of the PCR primers, mixed and PCR conditions, including Taq enzyme

The primers and conditions can be found in the referenced patent application. The PCR conditions were added to the protocol steps. We only used high fidelity polymerases, and did not use Taq polymerase, so this was not listed in the protocol or the materials.

Similarly, the authors should provide details of the vector backbone.

A new figure has been added (Figure 2) which consists of an overview of the cloning strategy and expression vector, including the backbone. The final expression plasmid, and the arrangement of heavy and light chain expression cassettes are described.

The single cell PCR method seems to be a derivative from the protocol that was started in the Nussenzweig lab (Wardeman 2002). Perhaps good to refer to that and to explain if and why these modifications here were chosen.

This method is a derivative of a more current protocol from the Nussenzweig lab, and this paper is cited in the references (Tiller, et al.). Additionally, a new paragraph was inserted into the discussion that addresses this similarity, and briefly describes the differences between the two.

T-cells do not have a heavy and a light chain. They have a TCR α and a TCR β chain (or TCR γ and TCR δ). These are very similar in size, with all having 1 IgV and 1 IgC domain, thus cannot be called 'heavy' and 'light'. The major differences with B cells is that T-cells do not just recognise antigen. The antigen peptides needs to be presented by MHC molecules, and thus require MHC tetramers with additional challenges due to the variability in MHC between individuals

The reviewer is correct. We modified the text to reflect this distinction between BCR and TCR and in the discussion.

The efficiency to obtain both an IgH and an IgL from a single B cells seems quite low from Figure 3. Is this representative? And can the authors state the total efficiency? How does this relate to other publications with single cell Ig amplification? Is this a technical challenge with cDNA reaction and/or PCR, or is this due to low purity of sorted cells? The stains in Fig 2 are not super strong, and perhaps inclusion of CD3, as well as IgM and IgD can be used to exclude T-cells and naive and IgM memory B cells.

The reviewer raises a good point. This gel is fairly representative of the amplification efficiencies for both heavy and light chain, the number of paired fragments is NOT representative. We have replaced with another set of gels to more accurately represent our normal results. We have added additional text in the Representative Results section referring to this figure and the efficiency observed.

Minor Concerns:

Abstract: 'interrogate of millions of B cells': remove first 'of'
Introduction, first sentence: change into 'molecules'

Both issues have been corrected in the text.